An ounce of prevention: stopping menopausal bone loss before it starts
一盎司的预防:在更年期骨质流失开始之前阻止它
基本信息
- 批准号:10324591
- 负责人:
- 金额:$ 18.24万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-01-15 至 2023-12-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdherenceAffectAffinityAlternative SplicingAmino AcidsAnimalsAntibodiesAntigensAphorismsApoptosisBacteriaBindingBiochemicalBiologyBiomechanicsBlocking AntibodiesBody CompositionBone DensityBone remodelingCSF1R geneCellsClinicalColony-Stimulating FactorsDataDevelopmentDoseDual-Energy X-Ray AbsorptiometryEnsureEstrogen Replacement TherapyEstrogen TherapyEstrogensFab ImmunoglobulinsFractureGoalsHip FracturesHomeostasisHumanImmunoglobulinsInnate Bone RemodelingInsectaKineticsLeadLibrariesMacrophage Colony-Stimulating FactorMeasurementMechanicsMediatingMembraneMenopauseMolecularMouse StrainsMusMutagenesisOsteoblastsOsteoclastsOsteoporosisOvariectomyPhage DisplayPhenotypePlayPostmenopausal OsteoporosisPreventionPrevention strategyProductionPropertyProtein IsoformsProtocols documentationRecombinantsRegimenReportingRiskRoleSelective Estrogen Receptor ModulatorsSeriesSkeletonTNFSF11 geneTechniquesTechnologyTestingTherapeuticWild Type MouseWithdrawalWomanWomen&aposs GroupWomen&aposs Healthantigen bindingbasebisphosphonatebonebone lossbone qualitybone turnovercytokineexperimental groupexpression vectorin vivoinhibitorlead candidatemicroCTneutralizing antibodynew therapeutic targetosteoclastogenesispreventreceptorrelease factorskeletalstoichiometry
项目摘要
Summary
The aphorism “an ounce of prevention is worth a pound of cure” very much applies to postmenopausal
osteoporosis. Immediately following menopause, bone loss rates can reach as high as 3-4% per year. At present,
there is no acceptable way to prevent this. A good prevention strategy would abrogate the increase in bone loss
without over-suppressing bone turnover and without off-target effects. Estrogen replacement therapy effectively
prevents menopausal bone loss, but the Women’s Health Initiative exposed the risks of ERT and it has largely
been abandoned as a preventive strategy. SERMs like ERT increase the risk of DVT. The long-term use of
bisphosphonates increases the risk of atypical fracture. To address this treatment gap, we propose a bold new
strategy, based on the biology of Colony Stimulating Factor 1.
Colony Stimulating Factor 1 (CSF1) is the principal colony stimulating factor released by osteoblasts and, in
addition to RANKL, is absolutely required for osteoclast formation. There are two major isoforms of CSF1, a
membrane-bound isoform (mCSF1) and a soluble, or circulating, isoform (sCSF1). The sCSF1 isoform has a
unique carboxy-terminus extension. Withdrawal of estrogen selectively up-regulates sCSF1 in osteoblasts, while
mCSF1 is unchanged. Importantly, an isoform-indiscriminate neutralizing antibody to CSF1 completely prevents
ovariectomy (OVX)-induced bone loss in mice. However, blocking both isoforms of CSF1 is not a viable
preventive strategy for estrogen-deficiency bone loss, because CSF1 is required for normal osteoclastogenesis.
We found that selectively deleting sCSF1 in vivo causes no phenotype, does not change the basal rate of bone
turnover, but protects mice against OVX-induced bone loss. These data point to sCSF1 as a novel therapeutic
target to prevent estrogen-deficiency bone loss. This R21 will test the hypothesis that selective inhibition of
the soluble isoform of CSF1 protects against estrogen-deficiency bone loss without affecting normal
bone remodeling or bone quality. In Specific Aim 1, phage display antibody selection will be employed to
rapidly develop an antibody that selectively inhibits sCSF1 by targeting the unique 73 amino acid c-terminus of
that isoform. In Specific Aim 2, the dose and timing of neutralizing antibody administration that completely
prevents bone loss in OVX wild type mice will first be determined using serial in vivo DXA bone density
measurements in OVX wild type mice. OVX animals treated with estrogen and OVX-sCSF1-/- mice will serve as
controls. Using the protocol that prevents a change in BMD from baseline, OVX and Sham-OVX wild type animals
will be treated with neutralizing antibody or isotype matched control antibody for 4 weeks. Comprehensive BMD
and body composition measurements, as well as ex vivo microCT, biochemical, biomechanical and
histomorphometric analyses will be undertaken. To ensure adequate rigor, these studies will be performed in
two different strains of mice. If successful, these studies will provide evidence for an entirely new way to prevent
postmenopausal bone loss before it begins.
总结
“一盎司的预防胜过一磅的治疗”这句格言非常适用于绝经后
骨质疏松绝经后不久,骨质流失率可高达每年3-4%。目前,
没有可接受的方法来防止这种情况。一个好的预防策略将消除骨丢失的增加
而不会过度抑制骨转换,也不会产生脱靶效应。雌激素替代疗法有效
预防绝经期骨质流失,但妇女健康倡议暴露了ERT的风险,
作为一种预防性战略被放弃。像ERT这样的SERM会增加DVT的风险。长期使用
二膦酸盐会增加非典型骨折的风险。为了解决这一治疗差距,我们提出了一个大胆的新方案,
策略,基于集落刺激因子1的生物学。
集落刺激因子1(CSF 1)是成骨细胞释放的主要集落刺激因子,
除RANKL外,是破骨细胞形成所必需的。CSF 1有两种主要亚型,
膜结合同种型(mCSF 1)和可溶性或循环同种型(sCSF 1)。sCSF 1亚型具有
独特的羧基末端延伸。雌激素的退出选择性地上调成骨细胞中的sCSF 1,
mCSF 1未发生变化。重要的是,针对CSF 1的同种型不加选择性中和抗体完全阻止了
卵巢切除术(OVX)诱导的小鼠骨丢失。然而,阻断CSF 1的两种亚型不是可行的方法。
雌激素缺乏性骨丢失的预防策略,因为正常的破骨细胞生成需要CSF 1。
我们发现,选择性地删除sCSF 1在体内不会引起表型,不会改变骨的基础率,
转换,但保护小鼠免受OVX诱导的骨丢失。这些数据表明sCSF 1是一种新的治疗药物,
预防雌激素缺乏性骨质流失。这个R21将检验选择性抑制
CSF 1的可溶性同种型防止雌激素缺乏性骨丢失而不影响正常
骨重建或骨质量。在特异性目标1中,将采用噬菌体展示抗体选择以
快速开发一种抗体,通过靶向sCSF 1独特的73个氨基酸的C-末端,
那个异形体在特定目标2中,完全不影响免疫应答的中和抗体给药的剂量和时间
将首先使用连续的体内DXA骨密度来确定OVX野生型小鼠中预防骨丢失的剂量
在OVX野生型小鼠中的测量。用雌激素处理的OVX动物和OVX-sCSF 1-/-小鼠将用作
对照使用防止BMD相对于基线变化的方案,OVX和假手术-OVX野生型动物
将用中和抗体或同种型匹配的对照抗体治疗4周。全面的骨密度
和身体成分测量,以及离体microCT,生物化学,生物力学和
将进行组织形态学分析。为了确保足够的严谨性,这些研究将在
两种不同品系的小鼠。如果成功,这些研究将为一种全新的预防方法提供证据。
绝经后骨质流失
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KARL Leonard INSOGNA其他文献
KARL Leonard INSOGNA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KARL Leonard INSOGNA', 18)}}的其他基金
Different Roles for Colony Stimulating Factor 1 Isoforms in Anabolic Therapy for Low Bone Mass
集落刺激因子 1 同工型在低骨量合成代谢治疗中的不同作用
- 批准号:
10585240 - 财政年份:2023
- 资助金额:
$ 18.24万 - 项目类别:
The Role of Sphingosine Kinases in Bone Anabolism
鞘氨醇激酶在骨合成代谢中的作用
- 批准号:
9274156 - 财政年份:2016
- 资助金额:
$ 18.24万 - 项目类别:
A novel SATB2 mutation illuminates bone anabolism
一种新的 SATB2 突变阐明了骨合成代谢
- 批准号:
8874913 - 财政年份:2014
- 资助金额:
$ 18.24万 - 项目类别:
A novel SATB2 mutation illuminates bone anabolism
一种新的 SATB2 突变阐明了骨合成代谢
- 批准号:
8758799 - 财政年份:2014
- 资助金额:
$ 18.24万 - 项目类别:
Calcitonin for Treating X-linked Hypophosphatemia
降钙素治疗 X 连锁低磷血症
- 批准号:
8319251 - 财政年份:2011
- 资助金额:
$ 18.24万 - 项目类别:
Calcitonin for treating X-linked hypophosphatemia
降钙素治疗 X 连锁低磷血症
- 批准号:
8193343 - 财政年份:2011
- 资助金额:
$ 18.24万 - 项目类别:
Conditional Deletion of PTHrP in Articular Chondrocytes
关节软骨细胞中 PTHrP 的条件性缺失
- 批准号:
7609121 - 财政年份:2008
- 资助金额:
$ 18.24万 - 项目类别:
Conditional Deletion of PTHrP in Articular Chondrocytes
关节软骨细胞中 PTHrP 的条件性缺失
- 批准号:
7509044 - 财政年份:2007
- 资助金额:
$ 18.24万 - 项目类别:
Microcomputed tomography device (Scanco microCT35)
微型计算机断层扫描设备(Scanco microCT35)
- 批准号:
7389328 - 财政年份:2007
- 资助金额:
$ 18.24万 - 项目类别:
IMPACT OF A PROTEIN SUPPLEMENT ON BONE MASS IN OLDER WOMEN
蛋白质补充剂对老年女性骨量的影响
- 批准号:
7194429 - 财政年份:2006
- 资助金额:
$ 18.24万 - 项目类别:
相似海外基金
I-Corps: Medication Adherence System
I-Corps:药物依从性系统
- 批准号:
2325465 - 财政年份:2023
- 资助金额:
$ 18.24万 - 项目类别:
Standard Grant
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
- 批准号:
490105 - 财政年份:2023
- 资助金额:
$ 18.24万 - 项目类别:
Operating Grants
An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
- 批准号:
10057526 - 财政年份:2023
- 资助金额:
$ 18.24万 - 项目类别:
Grant for R&D
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
- 批准号:
10772887 - 财政年份:2023
- 资助金额:
$ 18.24万 - 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
- 批准号:
10766947 - 财政年份:2023
- 资助金额:
$ 18.24万 - 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
- 批准号:
10594350 - 财政年份:2023
- 资助金额:
$ 18.24万 - 项目类别:
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
- 批准号:
10821172 - 财政年份:2023
- 资助金额:
$ 18.24万 - 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
- 批准号:
10748465 - 财政年份:2023
- 资助金额:
$ 18.24万 - 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
- 批准号:
10591441 - 财政年份:2023
- 资助金额:
$ 18.24万 - 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
- 批准号:
491109 - 财政年份:2023
- 资助金额:
$ 18.24万 - 项目类别:
Fellowship Programs